Antiplatelet therapy with clopidogrel in patients with atherosclerosis of lower limb arteries and diabetes type 2: problems and perspectives of pharmacogenetic approach
Abstract
The prevalence of atherosclerosis of the arteries of the lower extremities in the population is a socially significant problem in connection with high frequency of major amputation, disability and mortality in this group of patients. Diabetes 2 type along with smoking and arterial hypertension is a famous risk factor for peripheral atherosclerosis (in the limit of macrovascular complications). In Russian and foreign literature describes the clinical features, conventional methods of diagnosis and treatment of patients with obliterating atherosclerosis on the background of diabetes type 2. However, despite knowledge of the issue and the use of modern methods of diagnosis and treatment, the prognosis of the disease remains a serious, and level of cardiovascular death in this cohort is 6 times higher than the main population. In this regard, a perspective direction of the world and Russian scientists is to develop a method of pharmacogenetic testing as a instrument for personalized therapy of comorbid patients with peripheral atherosclerosis.
About the Authors
M. A. Andreyanova
FSBEI FPE Russian Medical Academy of Continuous Professional Education of Ministry of Healthcare of the Russian Federation
Russian Federation
Moscow
Russian Federation
Moscow
K. B. Mirzaev
FSBEI FPE Russian Medical Academy of Continuous Professional Education of Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Sector of molecular biological research
Moscow
D. A. Sychev
FSBEI FPE Russian Medical Academy of Continuous Professional Education of Ministry of Healthcare of the Russian Federation
Russian Federation
Moscow
Russian Federation
Moscow
A. G. Avtandilov
FSBEI FPE Russian Medical Academy of Continuous Professional Education of Ministry of Healthcare of the Russian Federation
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Fowkers F.G., Rudan D., Rudan I. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. The Lancet 382(9901). July 2013. DOI: 10.1016/S0140-6736(13)61249-0 · Source: PubMed.
2. Criqui M.H., Alberts M.J., Fowkes F.G., Hirsch A.T., O’Gara P.T., Olin J.W. American Heart Association Writing Group 2Atherosclerotic Peripheral Vascular Disease Symposium II: screening for atherosclerotic vascular diseases: should nationwide programs be instituted? Circulation. 2009 Jun 30; 119(25): e604 DOI:10.1161/CIRCULATIONAHA.108.191172.
3. Куликова А.Н., Лосев Р.З. Современные взгляды на диабетическую ангиопатию нижних конечностей (эпидемиология, факторы риска, этиопатогенез, атеросклероз при сахарном диабете). Часть I. Ангиология и сосудистая хирургия. 2005; 3: 14–20.
4. Куликова А.Н., Лосев Р.З., Тихонова Л.А. Современные взгляды на диабетическую ангиопатию нижних конечностей (диагностика поражения магистральных артерий при сахарном диабете). Часть II. Ангиология и сосудистая хирургия. 2006; 1: 25–31.
5. Рекомендации по диабету, преддиабету и сердечно-сосудистым заболеваниям. EASD/ESC, Lars Rydén, Peter J. Grant, Stefan D. Anker, Christian Berne, Francesco Cosentino et al. Российский кардиологический журнал. 2014; 3: 107.
6. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G. Intersociety consensus for the management of peripheral arterial disease (TASC II). J. Vasc. Surg. 2007; 45: Suppl. S: S5–S67.
7. Национальные рекомендации по ведению пациентов с заболеваниями артерий нижних конечностей. Ангиология и сосудистая хирургия. 2013, № 2. Том 19, приложение. Изд.: Ангиология ИНФО, М.: 2013.
8. Рекомендации Европейского общества кардиологов по диагностике и лечению заболеваний периферических артерий. EOK. M. Tendera, V. Aboyans, M-L.Bartelink, I. Baumgartner, D. Clément, J-P. Collet et al. Рациональная Фармакотерапия в Кардиологии. 2012; Приложение № 4 pdf.
9. Национальные рекомендации по ведению пациентов с сосудистой артериальной патологией (Российский Согласительный документ). Изд.: М.: 2010; 423.
10. Золоев Г.К. Облитерирующие заболевания артерий. Хирургическое лечение и реабилитация больных с утратой конечности. М.: Медицина, 2004; 432.
11. Баумгартнер Р., Ботта П. Ампутация и протезирование нижних конечностей. М.: Медицина, 2002; .504.
12. Price J.F., Mamode N., Smith F.B. et al. Haemostatic and rheological factors as predictors of restenosis following percutaneous transluminal angioplasty. Eur. J. Vasc. Endovasc. 1997; 14 (5): 392–398.
13. Powell R.J., Fillinger M., Walsh D.B. et al. Predicting outcome of angioplasty and selective stenting of multisegment iliac artery occlusive disease. J Vasc Surg. 2000; 32: 564–9.
14. Xando Díaz-Villamarín, Cristina Lucía DávilaFajardo, Luis Javier, Martínez-González, Pedro Carmona-Sáez, Jesús Sánchez-Ramos, María Jesús, Fernández-Quesada et al. Genetic polymorphisms inÁuence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty. Pharmacogenomics. 2016; 27. Source: PubMed. pdf.
15. Guidelines for the Management of patients with Peripheral Arterial Diseases, 2006.
16. Norgren L., Alwmark A., Angqvist K.A. et al. A stable prostacyclin analogue (iloprost) in the treatment of ischaemic ulcers of the lower limb: a Scandinavian-Polish placebo controlled, randomised multicenter study. Eur J Vasc Surg. 1990; 4: 463–7.
17. Rowe V.L., Lee W., Weaver F.A. et al. Patterns of treatment for peripheral arterial disease in the United States: 1996–2005. Journal of Vascular Surgery. 2009; 49: 4: 910–917.
18. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348 (9038): 1329–1339.
19. Jennings L.K. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009; 102: 248–257 [ PMID: 19652875 DOI:10.1160/TH09-03-0192 ]
20. Gawaz M. Langer H., May A.E. Platelets in inflammation and atherogenesis. J Clin Invest. 2005; 115: 3378–3384 [ PMID: 16322783 DOI: 10.1172/JCI27196 ].
21. Dorsam R.T., Kunapuli S.P. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004; 113: 340–345 [ PMID:14755328 DOI: 10.1172/JCI200420986 ].
22. Bonello L., Tantry U.S., Marcucci R., Blindt R., Angiolillo D.J., Becker R., Bhatt D.L., Cattaneo M., Collet J.P., Cuisset T., Gachet C., Montalescot G., Jennings L.K., Kereiakes D., Sibbing D., Trenk D., Van Werkum J.W., Paganelli F., Price M.J., Waksman R., Gurbel P.A. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010; 56: 919–933 [ PMID: 20828644 DOI: 10.1016/j.jacc.2010.04.047 ].
23. Geisler T., Anders N., Paterok M., Langer H., Stellos K., Lindemann S., Herdeg C., May A.E., Gawaz M. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care. 2007; 30: 372–374 [ PMID: 17259513 DOI: 10.2337/dc06-1625 ].
24. Spiliopoulos S., Pastromas G., Katsanos K., Kitrou P., Karnabatidis D., Siablis D. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol. 2013; 61: 2428–2434 [ PMID: 23602777 DOI: 10.1016/j.jacc.2013.03.036 ].
25. Savi P., Herbert J.M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005; 31: 174–183 [ PMID: 15852221 DOI: 10.1055/s-2005-869523 ]
26. Madsen E.H., Gehr N.R., Johannesen N.L., Schmidt E.B., Kristensen S.R. Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis. Platelets. 2011; 22: 537–546 [ PMID: 21591982 DOI: 10.3109/09537104.2011.577254 ].
27. Tepe G., Bantleon R., Brechtel K., Schmehl J., Zeller T., Claussen C.D., Strobl F.F. Management of peripheral arterial interventions with mono or dual antiplatelet therapy-the MIRROR study: a randomised and doubleblinded clinical trial. Eur Radiol. 2012; 22: 1998-2006 [ PMID: 22569995 DOI: 10.1007/s00330-012-2441-2 ].
28. Gurbel P.A., Antonino M.J., Tantry U.S. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol. 2009; 5: 989–1004 [ PMID:19575629 DOI: 10.1517/17425250903107772 ].
29. Pastromas G., Spiliopoulos S., Katsanos K., Diamantopoulos A., Kitrou P., Karnabatidis D., Siablis D. Clopidogrel responsiveness in patients undergoing peripheral angioplasty. Cardiovasc Intervent Radiol. 2013; 36: 1493–1499 [ PMID: 23408060 DOI: 10.1007/s00270-013-0577-3 ].
30. Kliger C., Babaev A., Shah B., Feit F., Slater J., Attubato M. Dual antiplatelet therapy responsiveness in patients undergoing percutaneous revascularization for peripheral arterial occlusive disease. J Am Coll Cardiol (JACC). 2012; 59: E2049–E2049.
31. Simon T., Verstuyft C., MaryKrause M. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 2009; 360 (4): 363–375.
32. Price M.J., Berger P.B., Teirstein P.S., Tanguay J.F., Angiolillo D.J., Spriggs D., Puri S., Robbins M., Garratt K.N., Bertrand O.F., Stillabower M.E., Aragon J.R., Kandzari D.E., Stinis C.T., Lee M.S., Manoukian S.V., Cannon C.P., Schork N.J., Topol E.J. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011; 305: 1097–1105 [ PMID: 21406646 DOI: 10.1001/jama.2011.290 ].
33. Мирзаев К.Б., Сычев Д.А., Андреев Д.А. Этнические особенности в Российской Федерации полиморфизма гена CYP2C19, ассоциированного с нарушением ответа на клопидогрел. Молекулярная медицина. 2014. 1; 13–21.
34. Мирзаев К.Б., Сычев Д.А., Андреев Д.А., Прокофьев А.Б. Значение фармакогенетического тестирования по CYP2C19 для персонализации применения антиагрегантов в кардиологической практике. Рациональная фармакотерапия в кардиологии. 2013; 4: 404408.
35. Mega J.L., Close S.L., Wiviott S.D. et al. Cytochrome P¬450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009; 360 (4): 354–362.
36. Shuldiner A.R., O’Connell J.R., Bliden K.P. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical effcacy of clopidogrel therapy. JAMA. 2009; 302 (8): 849–857.
37. Mega J.L., Simon T., Collet J.P. et al. Reduced ¬function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a metaanalysis. JAMA. 2010; 304 (16), 1821–1830.
38. Bauer T., Bouman H.J., van Werkum J.W., Ford N.F., ten Berg J.M., Taubert D. Impact of CYP2C19 variant genotypes on clinical effcacy of antiplatelet treatment with clopidogrel: systematic review and meta¬analysis. BMJ. 2011; 343: d4588.
39. Pare G., Mehta S.R., Yusuf S. et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 2010; 363 (18): 1704–1714.
40. Мешков А.Н. Фармакогенетика клопидогрела. Рациональная Фармакотерапия в Кардиологии. 2010; 6 (4): 569–572.
41. Montalescot G., Wiviott S.D., Braunwald E., Murphy S.A., Gibson C.M., McCabe C.H., Antman E.M. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373: 723–731 [ PMID: 19249633 DOI: 10.1016/S01406736(09)60441-4 ].
42. Patti G., Nusca A., Mangiacapra F., Gatto L., D’Ambrosio A., Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008; 52: 1128–1133 [ PMID: 18804738 DOI: 10.1016/j.jacc.2008.06.038 ].
43. Guo B., Tan Q., Guo D., Shi Z., Zhang C., Guo W. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in¬stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J. Vasc. Surg. 2014; 60 (4): 993–1001.
Review
For citations:
Andreyanova M.A., Mirzaev K.B., Sychev D.A., Avtandilov A.G. Antiplatelet therapy with clopidogrel in patients with atherosclerosis of lower limb arteries and diabetes type 2: problems and perspectives of pharmacogenetic approach. Pharmacogenetics and Pharmacogenomics. 2016;(2):27-31. (In Russ.)
Views:
400
Email this article 
Post a Comment 